Results 31 to 40 of about 17,592 (206)

Palbociclib releases the latent differentiation capacity of neuroblastoma cells.

, 2023
Neuroblastoma is the most common extracranial solid tumor in infants, arising from developmentally stalled neural crest-derived cells. Driving tumor differentiation is a promising therapeutic approach for this devastating disease.

core   +1 more source

Cyclin E1 expression and palbociclib efficacy in previously treated hormone receptor-positive metastatic breast cancer [PDF]

, 2019
PURPOSE: A large-panel gene expression analysis was conducted to identify biomarkers associated with the effectiveness of adding palbociclib to fulvestrant.
Liu, Y, Michiels, SP, Loi, S, Colleoni, M, Harbeck, N, André, F, Zhang, Z, Arnedos, M, Turner, NC, Bayar, MAM, Cristofanilli, M, DeMichele, A, Bartlett, CH, Zhu, Z, Giorgetti, C, Loibl, S   +15 more
core   +2 more sources

The Impact of Real-World Alternative Dosing Strategies of Palbociclib on Progression-Free Survival in Patients with Metastatic Breast Cancer

Current Oncology, 2022
Background: Palbociclib, a cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitor, in combination with letrozole or fulvestrant has been demonstrated to prolong the progression-free survival (PFS) in patients with hormone receptor-positive (HR+), human ...
Fulbert Fu, Jessica Kano, Julia Ma, Mera Guindy   +3 more
doaj   +1 more source

PALOMA-3: Phase III Trial of Fulvestrant With or Without Palbociclib in Premenopausal and Postmenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That Progressed on Prior Endocrine Therapy—Safety and Efficacy in Asian Patients

Journal of Global Oncology, 2017
Purpose: To assess efficacy and safety of palbociclib plus fulvestrant in Asians with endocrine therapy–resistant metastatic breast cancer. Patients and Methods: The Palbociclib Ongoing Trials in the Management of Breast Cancer 3 (PALOMA-3) trial, a ...
Hiroji Iwata, Seock-Ah Im, Norikazu Masuda, Young-Hyuck Im, Kenichi Inoue, Yoshiaki Rai, Rikiya Nakamura, Jee Hyun Kim, Justin T. Hoffman, Ke Zhang, Carla Giorgetti, Shrividya Iyer, Patrick T. Schnell, Cynthia Huang Bartlett, Jungsil Ro   +14 more
doaj   +1 more source

Palbociclib treatment alters nucleotide biosynthesis and glutamine dependency in A549 cells

Cancer Cell International, 2020
Background Aberrant activity of cell cycle proteins is one of the key somatic events in non-small cell lung cancer (NSCLC) pathogenesis. In most NSCLC cases, the retinoblastoma protein tumor suppressor (RB) becomes inactivated via constitutive ...
Lindsey R. Conroy, Pawel Lorkiewicz, Liqing He, Xinmin Yin, Xiang Zhang, Shesh N. Rai, Brian F. Clem   +6 more
doaj   +1 more source

In vivo efficacy of Palbociclib and Cetuximab in CF555 chordoma xenograft model_CF40

, 2021
DrugTargetsPalbociclib + CetuximabCDK4/6 + EGFRDose75mg/kg (Palbociclib) 20mg/kg (Cetuximab)RoutePO (Palbociclib) IP (Cetuximab)Scheduleqd to end (Palbociclib) 2xwklyx6 (Cetuximab) Duration of treatment42 dStrain of miceAthymic NudeTGI (day)98% (Day 42)p-
Dan Freed (4391989)
core   +1 more source

Indisulam synergizes with palbociclib to induce senescence through inhibition of CDK2 kinase activity.

PLoS ONE, 2022
Inducing senescence in cancer cells is emerging as a new therapeutic strategy. In order to find ways to enhance senescence induction by palbociclib, a CDK4/6 inhibitor approved for treatment of metastatic breast cancer, we performed functional genetic ...
Ziva Pogacar, Jackie L Johnson, Lenno Krenning, Giulia De Conti, Fleur Jochems, Cor Lieftink, Arno Velds, Leyma Wardak, Kelvin Groot, Arnout Schepers, Liqin Wang, Ji-Ying Song, Marieke van de Ven, Olaf van Tellingen, Rene H Medema, Roderick L Beijersbergen, Rene Bernards, Rodrigo Leite de Oliveira   +17 more
doaj   +1 more source

Real-world treatment patterns and effectiveness of palbociclib plus an aromatase inhibitor in patients with metastatic breast cancer aged 75 years or older

Frontiers in Oncology, 2023
BackgroundElderly patients are generally underrepresented in oncology clinical trials; therefore, real-world data are needed to inform clinical management of elderly patients with hormone receptor–positive/human epidermal growth factor receptor 2 ...
Adam Brufsky, Xianchen Liu, Benjamin Li, Lynn McRoy, Connie Chen, Rachel M. Layman, Hope S. Rugo   +6 more
doaj   +1 more source

Longitudinal circulating tumor DNA profiling in patients with advanced endometrial cancer using an off‐the‐shelf targeted NGS panel

Molecular Oncology, EarlyView.
Intratumour heterogeneity complicates precision management of advanced endometrial cancer. Circulating tumor DNA (ctDNA) offers a minimally invasive strategy to capture tumor evolution and therapeutic resistance. Here, we compare tumor‐agnostic NGS with tumor‐informed ddPCR, outlining their relative sensitivity, concordance, and clinical implications ...
Carlos Casas‐Arozamena, Karin Teien Lande, Eva Diaz, Ana Vilar, Juan Cueva, Efigenia Arias, Victoria Sampayo, Alicia Abalo, Nerea González, Eva Colás, Antonio Gil‐Moreno, Miguel Abal, Gema Moreno‐Bueno, Therese Sørlie, Kristina Lindemann, Laura Muinelo‐Romay   +15 more
wiley   +1 more source

The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells

Journal of Experimental & Clinical Cancer Research, 2018
Background Cell cycle regulators have gain attention as potential targets for anticancer therapy. Palbociclib is a selective inhibitor of the cyclin-dependent kinases 4 and 6 (CDK4/6), which coordinate the G1-S transition.
Daniele Cretella, Andrea Ravelli, Claudia Fumarola, Silvia La Monica, Graziana Digiacomo, Andrea Cavazzoni, Roberta Alfieri, Alessandra Biondi, Daniele Generali, Mara Bonelli, Pier Giorgio Petronini   +10 more
doaj   +1 more source